CEACAM5 and breast cancer: Most impressively, we found considerably improved performances for discrimination of breast cancer patients from either control group when miR-34a was combined with one of the tumor markers CEA or CA 15-3 resulting in higher AUCs and sensitivities at high specificities that are requested for differential diagnosis.